TABLE 2.
Summary of AEs
| Safety Population | Lorlatinib (n = 149) | Crizotinib (n = 142) |
|---|---|---|
| All-causality AEs, No. (%) | ||
| Any grade | 149 (100) | 140 (99) |
| Grade 3/4 | 115 (77) | 81 (57) |
| Grade 5 | 14 (9) | 7 (5) |
| Serious | 65 (44) | 45 (32) |
| Leading to temporary drug discontinuation | 92 (62) | 68 (48) |
| Leading to dose reduction | 34 (23) | 21 (15) |
| Leading to permanent drug discontinuation | 16 (11) | 15 (11) |
| Treatment-related AEs, No. (%) | ||
| Any grade | 145 (97) | 133 (94) |
| Grade 3/4 | 99 (66) | 55 (39) |
| Grade 5 | 2 (1) | 0 |
| Serious | 14 (9) | 9 (6) |
| Leading to temporary drug discontinuation | 58 (39) | 51 (36) |
| Leading to dose reduction | 31 (21) | 19 (13) |
| Leading to permanent drug discontinuation | 8 (5) | 8 (6) |
Abbreviation: AE, adverse event.